CA2395589A1 — Method for removing multimers of human serum albumin
Assigned to KM Biologics Co Ltd · Expires 2002-05-02 · 24y expired
What this patent protects
A method of eliminating human serum albumin polymers characterized by bringi ng a human serum albumin solution containing human serum albumin polymers into contact with an anion exchanger having been equilibrated with a buffer solution which has a salt concentration of 10 to 150 …
USPTO Abstract
A method of eliminating human serum albumin polymers characterized by bringi ng a human serum albumin solution containing human serum albumin polymers into contact with an anion exchanger having been equilibrated with a buffer solution which has a salt concentration of 10 to 150 mM and a pH value of 5 to 9.5.
Drugs covered by this patent
- Rapamune (sirolimus) · Pfizer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.